Journal article
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Movement disorders, Vol.35(11), pp.1999-2008
11/2020
DOI: 10.1002/mds.28206
PMCID: PMC8017468
PMID: 32798333
Abstract
The objective of this study was to assess neurofilament light chain as a Parkinson's disease biomarker.
We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson's disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson's disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers.
In the Parkinson's Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson's disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. Serum neurofilament light chain increased longitudinally in Parkinson's disease patients versus controls (P < 0.01). Motor scores were positively associated with neurofilament light chain, whereas some cognitive scores showed a negative association.
Neurofilament light chain in serum samples is increased in Parkinson's disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson's disease severity. Although the specificity of neurofilament light chain for Parkinson's disease is low, it is the first blood-based biomarker candidate that could support disease stratification of Parkinson's disease versus other cognate/neurodegenerative disorders, track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of neurofilament light chain as a biomarker of response to neuroprotective interventions remains to be assessed. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Details
- Title: Subtitle
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
- Creators
- Brit Mollenhauer - Paracelsus-Elena Klinik, Kassel, GermanyMohammed Dakna - Department of Neurology, University Medical Center Goettingen, Goettingen, GermanyNiels Kruse - Department of Neuropathology, University Medical Center Goettingen, Goettingen, GermanyDouglas Galasko - Department of Neurosciences, University of California, San Diego, San Diego, California, USATatiana Foroud - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USAHenrik Zetterberg - UK Dementia Research Institute at UCL, London, United KingdomSebastian Schade - Department of Neurology, University Medical Center Goettingen, Goettingen, GermanyRoland G Gera - Department of Medical Statistics, University Medical Center Goettingen, Goettingen, GermanyWenting Wang - Biostatistics, Biogen, Cambridge, Massachusetts, USAFeng Gao - Biostatistics, Biogen, Cambridge, Massachusetts, USAMark Frasier - The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USALana M Chahine - Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USAChristopher S Coffey - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USAAndrew B Singleton - Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USATanya Simuni - Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USADaniel Weintraub - Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAJohn Seibyl - Institute for Neurodegenerative Disorders, New Haven, Connecticut, USAArthur W Toga - Laboratory of Neuro Imaging, University of Southern California, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of University of Southern California, Los Angeles, California, USACaroline M Tanner - Department of Neurology, University of California San Francisco, San Francisco, California, USA, and Parkinson's Disease Research Education and Clinical Center, San Francisco Veterans Affairs Health Care System, San Francisco, California, USAKarl Kieburtz - Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USAKenneth Marek - Institute for Neurodegenerative Disorders, New Haven, Connecticut, USAAndrew Siderowf - Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAJesse M Cedarbaum - Coeruleus Clinical Sciences LLC, Woodbridge, Connecticut, USASamantha J Hutten - The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USAClaudia Trenkwalder - Paracelsus-Elena Klinik, Kassel, GermanyDanielle Graham - Discovery and Early Development Biomarkers, Biogen, Cambridge, Massachusetts, USA
- Resource Type
- Journal article
- Publication Details
- Movement disorders, Vol.35(11), pp.1999-2008
- DOI
- 10.1002/mds.28206
- PMID
- 32798333
- PMCID
- PMC8017468
- NLM abbreviation
- Mov Disord
- ISSN
- 0885-3185
- eISSN
- 1531-8257
- Grant note
- Z01 AG000949 / Intramural NIH HHS
- Language
- English
- Date published
- 11/2020
- Academic Unit
- Biostatistics
- Record Identifier
- 9984214728102771
Metrics
10 Record Views